Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immuno-Biological Laboratories Co's quarterly market cap
declined
from Mar. 2025 (円4,470 Mil) to Sep. 2025 (円4,424 Mil) but then
increased
from Sep. 2025 (円4,424 Mil) to Mar. 2026 (円12,498 Mil).
Immuno-Biological Laboratories Co's annual market cap
declined
from Mar. 2024 (円4,936 Mil) to Mar. 2025 (円4,470 Mil) but then
increased
from Mar. 2025 (円4,470 Mil) to Mar. 2026 (円12,498 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Immuno-Biological Laboratories Co's Enterprise Value for Today is 円8,445 Mil.
Immuno-Biological Laboratories Co (TSE:4570) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Immuno-Biological Laboratories Co Market Cap Related Terms
Immuno-Biological Laboratories Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co Market Cap Chart
TSE:4570 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Immuno-Biological Laboratories Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuno-Biological Laboratories Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Immuno-Biological Laboratories Co's Market Cap falls into.
Immuno-Biological Laboratories Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co (TSE:4570) has a Market Cap of 円9,258 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Immuno-Biological Laboratories Co and its competitors. According to the industry distribution chart, Immuno-Biological Laboratories Co ranks #864 out of 1423 companies in the Biotechnology industry, placing it in the top 60.7%.
Is Immuno-Biological Laboratories Co's Market Cap too high?
Immuno-Biological Laboratories Co's current Market Cap is 円9,258 Mil. Based on the distribution chart, Immuno-Biological Laboratories Co ranks #864 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuno-Biological Laboratories Co ranks #864 out of 1423 companies for Market Cap. This places Immuno-Biological Laboratories Co in the lower half of its industry. The industry median Market Cap is 115.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 115.88, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Immuno-Biological Laboratories Co and its competitors. For the Biotechnology industry, the median Market Cap is 115.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuno-Biological Laboratories Co's current Market Cap is 円9,258 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円578.92, compared to a current price of 円994.00 — trading 71.7% above its estimated fair value. The current Market Cap is 円9,258 Mil. Immuno-Biological Laboratories Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current Market Cap is 円9,258 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued.
The current stock price of 円994.00 is trading 71.7% above its estimated GF Value™ of 円578.92.
GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.
Key valuation signals for TSE:4570:
Market Cap: 円9,258 Mil
GF Value™: 円578.92 vs. price of 円994.00 (71.7% above fair value)
No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuno-Biological Laboratories Co Business Description
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
61GF Score
Get the complete analysis for TSE:4570
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4570 has been successfully added to your 
